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Isolated lung transplantation (LuTx) and liver trans-
plantation are established treatments for irreversible
lung and liver failure. Combined liver and lung
transplantation (cLiLuTx) is a less common, but
approved therapy of combined organ failure, mostly
applied in patients suffering from progressive cystic
fibrosis and advanced liver disease.We report a patient
who was listed for LuTx due to end-stage chronic
obstructive pulmonary disease and who developed
drug-induced acute hepatic failure. The only therapeu-
tic option was hyper-urgent cLiLuTx. To correct the
poor coagulation in order to reduce the per-operative
risk of bleeding, the liver was transplanted first. In
anticipation of the longer lung preservation time, cold
flushed lungs were preserved on a portable lung
perfusion device for ex vivo normothermic perfusion
for 11h 15min, transplanted sequentially off-pump,
and reperfused after a total ex vivo time of 13h 32min
and 16h for the first and second lung, respectively. Ten
months later, the patient is doingwell and no rejection
occurred. Normothermic ex vivo lung perfusion
may help to prolong preservation time, facilitating
long-distance transport and combined organ
transplantation.
Abbreviations: cLiLuTx, combined liver and lung
transplantation; cLiThTx, combined liver and thoracic
transplantation; CMV, cytomegalovirus; COPD, chron-
ic obstructive pulmonary disease; ET, Eurotransplant;
EVLP, ex vivo lung perfusion; FEV1, forced expiratory
volume in 1 s; HU, hyper-urgent; INR, international
normalized ratio; LiTx, liver transplantation; LuTx, lung
transplantation
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Introduction
Lung transplantation (LuTx) remains the ultimate therapeu-
tic option in selected patients with end-stage respiratory
insufficiency. Several underlying lung diseases are also
prone to develop hepatic complications. Most frequent
diseases with dual organ failure are cystic fibrosis and a1-
antitrypsin deficiency.On the other hand, patientswith end-
stage liver cirrhosis, who have developed treatment-
resistant porto-pulmonary hypertension are not amenable
to isolated liver transplantation (LiTx) because of the
associated morbidity and mortality that pulmonary hyper-
tension entails (1). To date, reports on combined liver and
lung transplantation (cLiLuTx) are scarce (2). We report on a
patient, primarily referred with end-stage chronic obstruc-
tive pulmonary disease (COPD) and listed for bilateral LuTx,
who developed drug-induced acute liver failure. The only
remaining life-saving therapy was cLiLuTx.
Case Report
A 62-year-old female (blood group: A, cytomegalovirus
[CMV]: þ, weight: 50 kg, length: 1m and 60 cm) was listed
for bilateral (sequential single) LuTx as a consequence of
end-stage respiratory failure due to COPD GOLD IV (forced
expiratory volume in 1 s [FEV1]: 31%; DLCO: 27%; BODE
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index: 7) with clear evidence of emphysema on computed
tomography. During pretransplant work-up (03/2013), 4
months prior to transplantation, the patient was initiated on
isoniazid (250mg/day) because of suspicion of latent
tuberculosis infection (IGRA: þ, intradermal test: ). In
addition to this, and in order to limit the frequence of
infectious COPD exacerbations, the macrolide antibiotic
roxithromycin (150mg; 3/week) was prescribed. Four
months later (07/2013), and 2 weeks after increasing the
intake of roxithromycin (150mg/day), the patient suddenly
developed anorexia and jaundice, and was urgently
admitted with acute hepatic failure (bilirubin: 21mg/dL,
aspartate transaminase: 3732U/L, international normalized
ratio [INR]: 1.9). Diagnosis of isoniazid (and possibly
roxithromycin)-induced acute liver failure (progressively
worsening encephalopathy and increasing INR> 10) was
made and intubationwas inevitable. Only remaining options
were either therapeutic de-escalation or hyper-urgent (HU)
cLiLuTx. After thorough multidisciplinary evaluation, a
request for HU cLiLuTx was sent to Eurotransplant (ET).
HU LiTx listing was granted immediately since the patient
fulfilled King’s College criteria. After rebuttal, ET thoracic
auditing committee granted listing for simultaneous HU
LuTx. Four days later, a liver graft and bilateral lung grafts
were procured from a 40-year-old male donor who died
from an intracranial bleeding (blood group: Oþ; CMV: þ,
weight: 55 kg, length: 1m and 68 cm). As a consequence of
severe coagulation disorder in the recipient and the
suspected risk of bleeding during LuTx, it was agreed to
transplant the liver first, while pulmonary grafts were
preserved during normothermic ex vivo lung perfusion
(EVLP; Figure 1). The liver was preserved with 4 L of
University of Wisconsin (UW) solution (Viaspan1, Du Pont,
Wilmington, DE) and stored on ice. The lungs were flushed
and cooled with 3 L of Perfadex1 (XVIVO, Go¨teborg,
Sweden [formerly named Vitrolife]), connected to the
Organ Care System (OCSTM) Lung device (Transmedics,
Andover, MA), perfused with 2 L OCSTM solution mixed
with 4U of packed red blood cells, and rewarmed to 378C.
Transport time was 4 h 27min. The liver was transplanted
orthotopically with veno-venous bypass and reperfused
after 5 h 20min of cold and 32min of warm ischemia. Total
operative time for LiTx was 6 h 29min. The lung procedure
was started 1 h 36min after finishing the LiTx. The INR at
thatmomentwas 1.3. Lungswere perfused on the portable
lung perfusion device for 11 h 15min with stable mean
pulmonary artery and peak airway pressures (Figure 2).
After a second cold Perfadex1 flush, the first (left) and
second (right) lung were implanted sequentially off-pump
through bilateral anterior thoracotomy and reperfused
after a total ex vivo time of 13 h 32min and 16h (including
2 h 17min and 4 h 45min cold ischemia), respectively. Total
operative time for LuTx was 6 h 29min. Postoperatively,
the patient regained consciousness upon improved liver
function, was extubated on day 7, discharged from
intensive care unit on day 12 and from hospital on day
60 after rehabilitation due to steroid-induced myopathy.
Immunosuppression was administered according to our
lung transplant protocol. Induction immunosuppressive
therapy consisted of 1000mg intravenous mycophenolate
mofetil, 3 days of rabbit antithymocyte globulin (3mg/kg/
day) and 3 125mg methylprednisolone during the
first postoperative day. Maintenance therapy consisted of
tacrolimus with a target trough-level of 12 ng/mL, myco-
phenolate mofetil (1000mg; 2/day) and a steroid taper
(starting at 0.4mg/kg/day from day 2).
Four months posttransplant, mild cholestasis was noticed
during routine check-up (gamma-glutamyltransferase: 262;
alanine aminotransferase: 320U/L, bilirubin: 0.64mg/dL)
and subsequent magnetic resonance cholangio-pancreati-
cography revealed an ischemic stenosis of the common bile
duct anastomosis. The stricture was successfully stented
by endoscopic retrograde cholangio-pancreaticography.
During 10 months follow-up, no rejection of the liver or
lung allograft has occurred and pulmonary function has
been excellent with a most recent predicted FEV1 of 94%.
Discussion
The limited clinical series in literature illustrate that cLiLuTx
is a viable and justifiable treatment option for selected
patients with either end-stage lung and advanced liver
disease, or in patients with end-stage liver disease and
secondarily compromised respiratory function (2).
Allocation rules for simultaneous organ transplantation in
Belgium are based on ET regulations: (1) Patients are listed
after the HU requests and (2) allocation of thoracic organs
precedes the liver, intestine, pancreas and kidneys. This
implicates that for cLiLuTx the lung allocation rules will be
followed (center-oriented allocation of lungs from local
donors within the hospital network). At our center, we have
experience with nine cases of combined liver and thoracic
transplantation with a median time on the waiting list of 72
days. The only HU request within this series is the currently
reported case, describing a sudden onset of drug-induced
Figure 1: Clinicalex vivo lungperfusionon theportableOCSTM
Lung perfusion device.
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acute liver failure. According to the literature, isoniazid is the
most common cause of tuberculostatic-induced hepatic
failure (3). Although the patient was administered isoniazid
for several months, the acute liver failure presented only 2
weeks after the increase of the roxithromycin intake. The
relation of the latter to fulminant hepatic failure is less well
documented (4,5). Easton-Carter et al (4) described a case
of a healthy 5-year-old boy who developed a generalized
jaundice, after a 5-day course of roxithromycin (50mg; 2/
day). Laboratory results revealed acute hepatic failure and 9
days later, the boy had to be transplanted. In case of rapidly
progressing liver failure and encephalopathy, LiTx remains
the only rescue therapy.
The additional respiratory failure confronted our patient
with a very high risk situation. It was felt that after an
Figure 2: Gradient for pulmonary artery pressure (A) and peak airway pressure (B) remained stable during 11 h 15min of normothermic ex
vivo lung perfusion (EVLP). The arrows indicatemoments of alveolar recruitment on the devicewith higher positive end-expiratory pressure
(7 cm H2O) and oxygen concentration (21%) in the bronchoscopy mode setting of the ventilator.
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isolated LiTx, it would be very difficult to wean this end-
stage COPD patient frommechanical ventilation, jeopardiz-
ing the outcome. Therefore, it was agreed that cLiLuTxwas
the only possible life-saving therapeutic option. Since the
risk of severe bleeding during LuTx was almost inevitable
due to the abnormal coagulation status, the decision was
made to prioritize the LiTx. In that way, the coagulation
status could be corrected and subsequent LuTx was
deemed to be safer.
To the best of our knowledge, this reversed transplant
procedure with the liver first has not been described. An
additional theoretical advantage of this sequence might be
the immunological protective effect that the liver may exert
on the lung graft. Since the first observation by Sir R. Calne,
this phenomenon has been attributed to different mech-
anisms, such as microchimerism, immune diversion or
creation of an antigen ‘‘sink’’ in which the liver diverts the
immune system away from the co-transplanted organ,
immune paralysis due to high antigen loads, and partial
tolerance induced by the liver’s ability to release soluble
class I antigens (6,7). This intriguing effect was illustrated in
a report by Daly et al (8) in a 50-year-old female suffering
from end-stage heart failure in combination with liver
cirrhosis and a high titer of HLA antibodies and panel
reactive antibodies (98%). It was hypothesized that
desensitization protocols would be insufficient and based
on the reported desensitizing effect of combined liver–
kidney transplantation in case of highly immunized patients,
the liver was transplanted first (9). Cardiac ischemic time
could be minimized to 4 h 17min. After transplantation
cross-match turned negative and anti-HLA antibody titers
decreased significantly. No rejection was shown in the first
15 months posttransplant.
In contrast to the heart, the tolerable ischemic time for the
lung is longer and therefore it could be assumed that the
transplant sequence in cLiLuTx could be safely inversed. In
fact, the first report on clinical EVLP by Steen et al (10) in
2001 described a total ischemic time for the lung of almost
13 h 30min. The same team described in 2007 a total ex
vivo time of 17 h for an initially nonacceptable donor lung in
which 6 h 30min of topical cooling and reconditioning with
normothermic perfusion were followed by 10 h 30min of
so-called topical ECMO at 88C (11). However, acceptable
lung ischemic time in Leuven is limited to 8–10h and since a
longer time was anticipated, the lungs were normothermi-
cally perfused and preserved. Based on our previous
experience with the portable lung perfusion device in the
Inspire trial (12,13), it was considered that normothermic
EVLPwould limit the cold ischemic injury and could prolong
ex vivo preservation. Review of the literature revealed that
11 h 15min of clinical EVLP in our case is the longest
reported (14). Experimental studies have shown that EVLP
was safe and feasible for even longer periods. The Toronto
group assessed porcine lungs for 12 h EVLP and demon-
strated that (i) donor lungs could be maintained without
inflicting significant added injury (15) and (ii) ongoing lung
injurywas prevented during 12 h EVLPwhen compared to a
cold storage control group (16).
The rationale of EVLP is to keep the lungs in a physiological
state which allows the pulmonary cells to remain metaboli-
cally active and viable for several hours. This period
provides a window for assessment and reconditioning of
previously unacceptable grafts, thereby enlarging the donor
pool as recently demonstrated in several clinical series (17–
20). The reconditioning can be attributed to several
mechanisms: dehydration by the high oncotic pressure in
the perfusate, removal of blood clots and inflammatory
cytokines with filters and recruitment of atelectatic areas
(14). Results from an ongoing clinical study (Inspire trial)
comparing cold storage with normothermic perfusion
are awaited to determine if extended normothermic
EVLP is safe and superior to cold storage (12). If this
would be demonstrated, new avenues could be opened to
preserve and recondition lungs for a longer period of time.
Until then, cold storage remains the gold standard for lung
preservation.
In conclusion, four unique aspects are illustrated in this
case: (1) Isoniazid is a rare cause of acute liver failure and
indication for HU LiTx. In this patient, roxithromycin may
also have exerted a role. (2) Acute liver failure developed in
an already actively listed LuTx candidate, rendering isolated
LiTx probably futile and making HU cLiLuTx the only option.
(3) To correct the poor coagulation, LiTx was performed
prior to LuTx. (4) Clinical prolonged normothermic EVLP for
11 h is feasible. This technique may help to prolong
preservation time facilitating long-distance transport and
combined organ transplantation.
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